CytoMed Therapeutics announced Friday that it received a Nasdaq notice of non-compliance after its closing bid price stayed below $1 for 30 consecutive business days. The company has until April 5, 2027, to restore compliance by keeping its closing bid price at or above $1 for at least 10 consecutive business days. CytoMed may qualify for another 180-day extension if it meets Nasdaq's other listing requirements, including the minimum market value of publicly held shares. A written notice outlining its intention to cure the deficiency must be submitted to Nasdaq during the second period, with a reverse stock split among the possible measures. Shares fell 5.81%.
CytoMed Therapeutics Limited Ordinary SharesCytoMed received a Nasdaq non-compliance notice for its sub-$1 bid price, threatening delisting unless it cures the deficiency.
